glp-1 kidney news Receptor Agonists and Diabetic Disease: A Call of Attention to Nephrologists Association of glucagon-like peptide-1 receptor

There is a real sense now of a rapid expansion in the area of novel medications in the area of obesity. Claire Davies, diabetes and endocrinology specialist pharmacist at Gateshead Health NHS Foundation Trust, said: This is an exciting new piece of research and shows the ongoing rapid advancement of GLP-1 and other therapies for diabetes and obesity

Furthermore, they can be unsafe and, in some cases, have been linked with death

L-Carnitine 30ml 300mg/ml &amp

None of these platforms is risk-free the boxed warning for thyroid C-cell tumors applies to both semaglutide and tirzepatide based on rodent studies, and GLP-1 medications carry well-documented GI side effects (nausea, vomiting, diarrhea, constipation) plus less-common documented events including pancreatitis, gallbladder disease, and acute kidney injury